Skip to content
Triangle logo TriangleGet started
← Study library

NCT02037256 · REGISTRY CONDITION SEARCH

Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
NA
Status at capture
COMPLETED
Registry last update
2021-05-10

This clinical trial studies peripheral blood hemapoietic stem cell mobilization with the combination of bortezomib and G-CSF (filgrastim) in multiple myeloma and non-Hodgkin lymphoma patients.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

>= 2 Fold Increase in Circulating PBSC's

→

outcome · POSTED

Time to Neutrophil Engraftment

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Voluntary written informed consent form before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care * Diagnosis of B-type NHL or with multiple myeloma and eligible for autologous transplantation * No more than 3 prior regimens of chemotherapy (Rituximab is not considered chemotherapy) and 4 weeks out of Bortezomib treatment for MM * Karnofsky performance status of \> 50% * The patient has recovered from all acute toxic effects of prior chemotherapy * White blood cell (WBC) \> 3.0 x 10\^9/L * Absolute neutrophil count \> 1.5 x 10\^9/L * Platelet count \> 100 x 10\^9/L * Serum creatinine =\< 2.2 * Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvate transaminase (SGPT) less than two times the upper limit of normal (ULN) * Total bilirubin less than two times the ULN * Left ventricle ejection fraction \> 50% (by normal echocardiogram \[ECHO\] or multi gated acquisition scan \[MUGA\] scan) * Diffusing capacity of the lung for carbon monoxide (DLCO) \> 50% * Forced vital capacity \> 50% of predicted * Negative for human immunodeficiency virus (HIV) * Female subject is either post-menopausal for at least 1 year before the screening visit, is surgically sterilized or if they are of childbearing potential , agree to use 2 effective methods of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) from the time of signing the informed consent form through 30 days after the last dose of Bortezomib, or agree to completely abstain from heterosexual intercourse; women of child bearing potential agree to use an approved form of contraception; male subject, even if surgically sterilized (i.e., status post-vasectomy) must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourse for the duration of the study Exclusion Criteria: * Patient has a platelet count of \< 100x 10\^9/L within 14 days before enrollment * Patient has an absolute neutrophil count of ANC \<1.5 x 10\^9/L within 14 days before enrollment * Patient has creatinine of \> 2.2 MG/DL within 14 days before enrollment * Patient has \> 1.5 x ULN total bilirubin * Patient has \>= grade 2 peripheral neuropathy within 14 days before enrollment * Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities; prior to study entry, any electrocardiogram (ECG) abnormality at screening has to be documented by the investigator as not medically relevant * Patient has hypersensitivity to Bortezomib, boron or mannitol * Female subject is pregnant or breast-feeding; confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (b-hCG) pregnancy test result obtained during screening; pregnancy testing is not required for post-menopausal or surgically sterilized women * Participation in clinical trials with other investigational drugs not included in this trial, within 14 days before enrollment and throughout the duration of this trial * Serious medical or psychiatric illness likely to interfere with participation in this clinical study * A co-morbid condition which, in the view of the investigators, renders the patient at high risk for this study * An acute medical condition resulting from prior chemotherapy * Brain metastases or carcinomatous meningitis * Acute infection * Fever (temp \> 38 degrees Celsius \[C\]/100.4 degrees Fahrenheit \[F\]) * Patients of child-bearing potential unwilling to implement adequate birth control * Patients who have deterioration of their clinical status or laboratory parameters between the time of enrollment and transplant (such that they no longer meet entry criteria) may be removed from study at the discretion of the treating physician or principal investigator * Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy * Radiation therapy within 3 weeks before randomization; enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy
healthy Volunteers
false
maximum Age
70 Years
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    GROUP A: Bortezomib administered in the evening after comploetion of G-CSF collection or on day 6 of mobilization with G-CSF.
    intervention Names
    1. Drug: bortezomib
    2. Biological: filgrastim
    3. Procedure: autologous hematopoietic stem cell transplantation
    label
    A Treatment (bortezomib and filgrastim)
    type
    EXPERIMENTAL
  2. description
    GROUP B: Bortexomib administered on days 4 \& day 7, before administration of filgrastim.
    intervention Names
    1. Drug: bortezomib
    2. Biological: filgrastim
    3. Procedure: autologous hematopoietic stem cell transplantation
    label
    B Treatment (bortezomib and filgrastim)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. A Treatment (bortezomib and filgrastim)
    2. B Treatment (bortezomib and filgrastim)
    description
    Given IV
    name
    bortezomib
    other Names
    1. LDP 341
    2. MLN341
    3. VELCADE
    type
    DRUG
  2. arm Group Labels
    1. A Treatment (bortezomib and filgrastim)
    2. B Treatment (bortezomib and filgrastim)
    description
    Given SC
    name
    filgrastim
    other Names
    1. G-CSF
    2. Neupogen
    type
    BIOLOGICAL
  3. arm Group Labels
    1. A Treatment (bortezomib and filgrastim)
    2. B Treatment (bortezomib and filgrastim)
    description
    Undergo autologous hematopoietic stem cell transplantation
    name
    autologous hematopoietic stem cell transplantation
    type
    PROCEDURE
Study design
allocation
NON_RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
23
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Participants with \>= 2 fold increase in circulating PBSC's in blood and in apheresis collections in up to 4-days collection
    measure
    >= 2 Fold Increase in Circulating PBSC's
    time Frame
    Up to 6 months
secondary Outcomes
  1. description
    Estimated Median Time to Neutrophil Engraftment, ANC 500
    measure
    Time to Neutrophil Engraftment
    time Frame
    Up to 6 months
Full study description
brief Summary
This clinical trial studies peripheral blood hemapoietic stem cell mobilization with the combination of bortezomib and G-CSF (filgrastim) in multiple myeloma and non-Hodgkin lymphoma patients.
detailed Description
PRIMARY OBJECTIVES: I. To estimate if addition of Bortezomib to the mobilization protocol will result with an increase in the levels of circulating peripheral blood stem cells (PBSCs) by at least 2-fold in blood and in the apheresis collections in up to 4-days collection protocol. II. To assess whether time to neutrophil engraftment is 12 days or less, the historical value. SECONDARY OBJECTIVES: I. To test for co-mobilization of lymphoma or myeloma cells by bortezomib and G-CSF using real time polymerase chain reaction (PCR) for non-Hodgkin lymphoma (NHL) patients and by flow cytometry (cluster of differentiation \[CD\]38+/CD138+ cell) for multiple myeloma (MM) patients. II. To determine the effect of Bortezomib on the extent of mobilization of dendritic cells subsets, plasmacytoid dendritic cell (pDC)1 and pDC2 and DC1/DC2 ratio by flow cytometry.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-3001d4063de9e214c2fe
      requested nct id
      NCT02037256
      primary nct id
      NCT02037256
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      8b9a346048372591e3ee0de631ceead25528dc1d384a69971d454af93b26921d
      payload sha256
      d78ae9ebf41929437b49e9546f7827021e660149ba40d1933af6766f2d331106
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-3001d4063de9e214c2fe
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02037256
      occurrences
      1. context exact
        NCT02037256
        end
        11
        exact text
        NCT02037256
        start
        0
      offset unit
      unicode_code_points
      query cond
      Hairy Cell Leukemia
      query disease state id
      ds-hairy-cell-leukemia
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hairy-cell-leukemia-000.json
      source file sha256
      8b9a346048372591e3ee0de631ceead25528dc1d384a69971d454af93b26921d
      source json pointer
      /studies/40/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      52f836a48bea08c973f7c26d223604003e5cbbb2532bbbe45ed49b433ed61f2c
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-c90d7a7ce9bdad4c7680
      requested nct id
      NCT02037256
      primary nct id
      NCT02037256
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      8c03325fbe3965c6439baca5a77d3e70a7f167ca6c3fadbee37a13cc7ad73d51
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-c90d7a7ce9bdad4c7680
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02037256
      occurrences
      1. context exact
        NCT02037256
        end
        11
        exact text
        NCT02037256
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/834/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      52f836a48bea08c973f7c26d223604003e5cbbb2532bbbe45ed49b433ed61f2c
    3. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-ee530bd5b28d42f5f6b8
      requested nct id
      NCT02037256
      primary nct id
      NCT02037256
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
      payload sha256
      ebd9848d5a0a6bc743ed1043186103ab6aa40e6bf72aae293c8693f72d3ea0e7
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-ee530bd5b28d42f5f6b8
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02037256
      occurrences
      1. context exact
        NCT02037256
        end
        11
        exact text
        NCT02037256
        start
        0
      offset unit
      unicode_code_points
      query cond
      Small Intestine Cancer
      query disease state id
      ds-small-intestine-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-small-intestine-cancer-000.json
      source file sha256
      69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
      source json pointer
      /studies/98/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      52f836a48bea08c973f7c26d223604003e5cbbb2532bbbe45ed49b433ed61f2c

    Preserved source evidence · Not medical advice